[HTML][HTML] Molecular characteristics of uveal melanoma: insights from the cancer genome atlas (TCGA) project
MF Bakhoum, B Esmaeli - Cancers, 2019 - mdpi.com
The Cancer Genome Atlas (TCGA) uveal melanoma project was a comprehensive multi-
platform deep molecular investigation of 80 uveal melanoma primary tissue samples …
platform deep molecular investigation of 80 uveal melanoma primary tissue samples …
[HTML][HTML] Re-definition of claudin-low as a breast cancer phenotype
The claudin-low breast cancer subtype is defined by gene expression characteristics and
encompasses a remarkably diverse range of breast tumors. Here, we investigate genomic …
encompasses a remarkably diverse range of breast tumors. Here, we investigate genomic …
[HTML][HTML] PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
BD Lehmann, JA Bauer, JM Schafer… - Breast Cancer …, 2014 - Springer
Introduction Triple negative breast cancer (TNBC) is a heterogeneous collection of
biologically diverse cancers, which contributes to variable clinical outcomes. Previously, we …
biologically diverse cancers, which contributes to variable clinical outcomes. Previously, we …
[HTML][HTML] Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis
Fatty acid β-oxidation (FAO) is the main bioenergetic pathway in human prostate cancer
(PCa) and a promising novel therapeutic vulnerability. Here we demonstrate therapeutic …
(PCa) and a promising novel therapeutic vulnerability. Here we demonstrate therapeutic …
[HTML][HTML] Autotaxin and breast cancer: Towards overcoming treatment barriers and sequelae
MGK Benesch, X Tang, DN Brindley - Cancers, 2020 - mdpi.com
After a decade of intense preclinical investigations, the first in-class autotaxin inhibitor,
GLPG1690, has entered Phase III clinical trials for idiopathic pulmonary fibrosis. In the …
GLPG1690, has entered Phase III clinical trials for idiopathic pulmonary fibrosis. In the …
[HTML][HTML] Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
M Zeng, NP Kwiatkowski, T Zhang, B Nabet, M Xu… - Elife, 2018 - elifesciences.org
High-grade serous ovarian cancer is characterized by extensive copy number alterations,
among which the amplification of MYC oncogene occurs in nearly half of tumors. We …
among which the amplification of MYC oncogene occurs in nearly half of tumors. We …
A PGC1α-mediated transcriptional axis suppresses melanoma metastasis
C Luo, JH Lim, Y Lee, SR Granter, A Thomas… - Nature, 2016 - nature.com
Melanoma is the deadliest form of commonly encountered skin cancer because of its rapid
progression towards metastasis,. Although metabolic reprogramming is tightly associated …
progression towards metastasis,. Although metabolic reprogramming is tightly associated …
[HTML][HTML] Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma
AM Unni, WW Lockwood, K Zejnullahu, SQ Lee-Lin… - Elife, 2015 - elifesciences.org
Human lung adenocarcinomas (LUAD) contain mutations in EGFR in∼ 15% of cases and in
KRAS in∼ 30%, yet no individual adenocarcinoma appears to carry activating mutations in …
KRAS in∼ 30%, yet no individual adenocarcinoma appears to carry activating mutations in …
[HTML][HTML] KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
Inhibitors that target the receptor tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase
(MAPK) pathway have led to clinical responses in lung and other cancers, but some patients …
(MAPK) pathway have led to clinical responses in lung and other cancers, but some patients …
[HTML][HTML] Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer
YP Kang, L Torrente, A Falzone, CM Elkins, M Liu… - Elife, 2019 - elifesciences.org
NRF2 is emerging as a major regulator of cellular metabolism. However, most studies have
been performed in cancer cells, where co-occurring mutations and tumor selective …
been performed in cancer cells, where co-occurring mutations and tumor selective …